Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Reversibility of hepatic fibrosis and cirrhosis—is it all hype?

Nature Clinical Practice Gastroenterology & Hepatology volume 4, pages 236–237 (2007)Cite this article

Now that the idea that hepatic fibrosis is reversible is taking root, many clinicians are beginning to ask why, if fibrosis is reversible, is there so little progress in the clinical setting, and will patients ever really benefit from antifibrotic therapies? Underlying such questions is a subtle cynicism that the reversibility of fibrosis and cirrhosis has been overhyped—yet another example of the medical media 'spin machine' giving false hope to desperate patients. The situation has been fueled by the actions of ambitious institutional press relations officers. One such example is the worldwide media focus on the use of sulfasalazine to treat hepatic fibrosis, with claims that half of all liver deaths could be avoided1 even though the drug's reported efficacy was based on a single study in rodents.

So what is the truth, and how do we maintain perspective? First of all, progress has been tremendous. The mere idea that fibrosis can regress when the initial disease is controlled or cured is exciting, given the decades of dogma that suggested scar formation was a unidirectional pathway. Ample evidence that fibrosis regresses with control of hepatitis B, hepatitis C, or other chronic liver diseases2 attests to the tremendous regenerative power of the liver, and the rapid progress made in the development of targeted antiviral and disease-specific treatments. Without such advances a discussion of reversibility would have been moot, but this discussion has raised some semantic issues that sow controversy and obscure continued progress. Specifically, use of the term 'reversal' implies a complete return to normal histology, whereas a better term would be 'regression'—a more accurate and relevant term that indicates improvement in fibrosis without necessarily a return to normal histology. Of equal importance, stasis of disease or delayed progression are clinically meaningful, as they might prevent the development of cirrhosis, which is the only stage of chronic liver disease associated with significant and predictable complications.3 A related issue is the failure of some clinical studies to distinguish between cirrhosis, which connotes distinct architectural and structural changes (including nodules of fibrosis that encapsulate hepatocytes), and advanced fibrosis, which lacks these features.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. British Broadcasting Corporation, London (2006) Drug 'may reverse liver disease'. [http://news.bbc.co.uk/2/hi/health/5382172.stm] (accessed 22 March 2007)

  2. Bonis PA et al. (2001) Is liver fibrosis reversible? N Engl J Med 344: 452–454

    Article  CAS  Google Scholar 

  3. Nagula S et al. (2006) Histological–hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J Hepatol 44: 111–117

    Article  Google Scholar 

  4. Issa R et al. (2004) Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126: 1795–1808

    Article  CAS  Google Scholar 

  5. Herold C et al. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 21: 260–265

  6. Ratziu V et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898–1906

    Article  Google Scholar 

  7. Gawrieh S et al. (2005) Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl 11: 1207–1213

    Article  Google Scholar 

  8. Foucher J et al. (2006) Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 55: 403–408

    Article  CAS  Google Scholar 

  9. Ngo Y et al. (2006) A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 52: 1887–1896

    Article  CAS  Google Scholar 

  10. Huang H et al. (2006) Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130: 1679–1687

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Box 1123, Mount Sinai School of Medicine, Room 11-70C, 1425 Madison Avenue, New York, NY 10029-6574, USA scott.friedman@mssm.edu

Authors and Affiliations

  1. SL Friedman is Fishberg Professor and Chief of the Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA.,

    Scott L Friedman

Authors
  1. Scott L Friedman
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The author has declared associations with the following companies/organizations: Angion Biomedica, Intercept, Conatus, XTL, Stromedix, Breath ID, Biogen Idec, Genzyme, Gilead, Glaxo Smith Kline, Novartis and Pro-Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friedman, S. Reversibility of hepatic fibrosis and cirrhosis—is it all hype?. Nat Rev Gastroenterol Hepatol 4, 236–237 (2007). https://doi.org/10.1038/ncpgasthep0813

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpgasthep0813

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing